^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD79b-targeted antibody-drug conjugate

    Related drugs:
    2d
    A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas. (PubMed, Sci Rep)
    POLA demonstrated robust single-agent antitumor activity in vivo, including in PDX models derived from patients with ibrutinib-resistant MCL. This signature likely reflects core pathways associated with POLA resistance and highlights potential novel therapeutic vulnerabilities. These findings strongly support further clinical investigation of POLA in combination with VEN as a BCL2- and MCL1-targeting therapeutic strategy in patients with R/R MCL and BCL2-positive R/R DLBCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD79B (CD79b Molecule)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Polivy (polatuzumab vedotin-piiq)
    14d
    Pola-ZRCHP: Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    23d
    Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation. (PubMed, Ann Hematol)
    Previous studies have shown that the combination of the second-generation BTKi zanubrutinib and polatuzumab vedotin, within the R-CHOP regimen, yielded higher response rates in preliminary clinical studies; however, the efficacy of this combination remains unclear. Notably, the combination showed superior synergistic efficacy in GCB-subtype cells. In conclusion, these findings provide a novel mechanistic rationale for combining zanubrutinib and polatuzumab vedotin in DLBCL treatment, regardless of cell-of-origin subtype.
    Journal
    |
    CD79B (CD79b Molecule)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq)
    27d
    ALLG NHL44: A Phase 2, Multicenter, Single-Arm Study to Evaluate Polatuzumab vedotin-Rituximab with/without Radiotherapy as a Bridging Therapy in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Prior to CD19 CAR-T Cell Therapy (ACTRN12626000586314)
    P2, N=47, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq)
    1m
    POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    1m
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    2ms
    A Prospective, Multicenter, Single-arm Phase II Study Evaluating the Efficacy and Safety of Polatuzumab Vedotin in Combination with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZRCHP) in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (ChiCTR2600119915)
    P2, N=48, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    2ms
    A single-arm, prospective, phase II study of Glofitamab in combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin,and Prednisone (Pola-R-CHP) to optimize primary therapy in patients with high-risk Diffuse Large B-Cell Lymphoma assessed by interim FDG PET and ctDNA (ChiCTR2600118538)
    P2, N=42, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial • Circulating tumor DNA
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    2ms
    Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. (PubMed, Blood)
    This is the first bispecific-ADC combination therapy study in MCL. (Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT03671018).
    P2 data • Journal
    |
    TP53 (Tumor protein P53) • CD79B (CD79b Molecule)
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    2ms
    Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    2ms
    Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=5, Terminated, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Funding
    Trial completion date • Trial termination
    |
    cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq)
    2ms
    Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule)
    |
    Polivy (polatuzumab vedotin-piiq)